HomeBUSINESS
BUSINESS

Kyowa Kirin Eyes US Resubmission for Nouriast Next Year
(Oct.18.2017)

Kyowa Hakko Kirin said on October 17 that it intends to resubmit its application in the US for its Parkinson’s disease treatment istradefylline (KW-6002), known as Nouriast in Japan, as early as next year. The drug was rejected by the FDA in 2008 due to efficacy concerns ...
(LOG IN FOR FULL STORY)

News Calendar